Mirum Pharmaceuticals director plans $185K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mirum Pharmaceuticals, Inc. director Saira Ramasastry reported an intended sale of 2,000 common shares, with an aggregate market value of 184,560.00 and an approximate sale date of November 16, 2026. The notice also lists a cash-paid stock-option exercise of 2,000 shares acquired from the issuer on November 16, 2026, and August 10, 2026 as the plan adoption or instruction date for reliance on Rule 10b5-1. It lists 65,282,044 common shares outstanding.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Stock Option Exercise financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Rule 10b5-1 date is listed for Saira Ramasastry's planned MIRM sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.